vs
Orthofix Medical Inc.（OFIX）与WORTHINGTON ENTERPRISES, INC.（WOR）财务数据对比。点击上方公司名可切换其他公司
WORTHINGTON ENTERPRISES, INC.的季度营收约是Orthofix Medical Inc.的1.5倍（$327.5M vs $219.9M），WORTHINGTON ENTERPRISES, INC.净利率更高（8.3% vs -1.0%，领先9.4%），WORTHINGTON ENTERPRISES, INC.同比增速更快（19.5% vs 2.0%），WORTHINGTON ENTERPRISES, INC.自由现金流更多（$39.1M vs $16.8M）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
沃辛顿实业是一家总部位于美国俄亥俄州哥伦布市的工业制造企业，下设消费品和建筑产品两大业务板块，设计生产丙烷、氧气、氦气压力容器，制冷及工业气瓶，露营与家用气瓶，以及用于存储、处理、加热、扩容和流量控制的供水系统罐体等多元化产品。
OFIX vs WOR — 直观对比
营收规模更大
WOR
是对方的1.5倍
$219.9M
营收增速更快
WOR
高出17.5%
2.0%
净利率更高
WOR
高出9.4%
-1.0%
自由现金流更多
WOR
多$22.3M
$16.8M
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $327.5M |
| 净利润 | $-2.2M | $27.3M |
| 毛利率 | 71.1% | 25.8% |
| 营业利润率 | 0.2% | 3.7% |
| 净利率 | -1.0% | 8.3% |
| 营收同比 | 2.0% | 19.5% |
| 净利润同比 | 92.4% | -3.3% |
| 每股收益（稀释后） | $-0.05 | $0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXWOR
| Q4 25 | $219.9M | $327.5M | ||
| Q3 25 | $205.6M | $303.7M | ||
| Q2 25 | $203.1M | — | ||
| Q1 25 | $193.6M | — | ||
| Q4 24 | $215.7M | — | ||
| Q3 24 | $196.6M | — | ||
| Q2 24 | $198.6M | — | ||
| Q1 24 | $188.6M | — |
净利润OFIXWOR
| Q4 25 | $-2.2M | $27.3M | ||
| Q3 25 | $-22.8M | $35.1M | ||
| Q2 25 | $-14.1M | — | ||
| Q1 25 | $-53.1M | — | ||
| Q4 24 | $-29.1M | — | ||
| Q3 24 | $-27.4M | — | ||
| Q2 24 | $-33.4M | — | ||
| Q1 24 | $-36.0M | — |
毛利率OFIXWOR
| Q4 25 | 71.1% | 25.8% | ||
| Q3 25 | 72.2% | 27.1% | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
营业利润率OFIXWOR
| Q4 25 | 0.2% | 3.7% | ||
| Q3 25 | -8.3% | 3.0% | ||
| Q2 25 | -7.9% | — | ||
| Q1 25 | -25.2% | — | ||
| Q4 24 | -5.3% | — | ||
| Q3 24 | -9.6% | — | ||
| Q2 24 | -12.5% | — | ||
| Q1 24 | -15.6% | — |
净利率OFIXWOR
| Q4 25 | -1.0% | 8.3% | ||
| Q3 25 | -11.1% | 11.6% | ||
| Q2 25 | -6.9% | — | ||
| Q1 25 | -27.4% | — | ||
| Q4 24 | -13.5% | — | ||
| Q3 24 | -13.9% | — | ||
| Q2 24 | -16.8% | — | ||
| Q1 24 | -19.1% | — |
每股收益（稀释后）OFIXWOR
| Q4 25 | $-0.05 | $0.55 | ||
| Q3 25 | $-0.57 | $0.70 | ||
| Q2 25 | $-0.36 | — | ||
| Q1 25 | $-1.35 | — | ||
| Q4 24 | $-0.76 | — | ||
| Q3 24 | $-0.71 | — | ||
| Q2 24 | $-0.88 | — | ||
| Q1 24 | $-0.95 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $180.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $962.6M |
| 总资产 | $850.6M | $1.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXWOR
| Q4 25 | $82.0M | $180.3M | ||
| Q3 25 | $62.9M | $167.1M | ||
| Q2 25 | $65.6M | — | ||
| Q1 25 | $58.0M | — | ||
| Q4 24 | $83.2M | — | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $26.4M | — | ||
| Q1 24 | $27.0M | — |
总债务OFIXWOR
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXWOR
| Q4 25 | $450.0M | $962.6M | ||
| Q3 25 | $442.5M | $959.1M | ||
| Q2 25 | $458.3M | — | ||
| Q1 25 | $458.3M | — | ||
| Q4 24 | $503.1M | — | ||
| Q3 24 | $525.9M | — | ||
| Q2 24 | $546.0M | — | ||
| Q1 24 | $570.3M | — |
总资产OFIXWOR
| Q4 25 | $850.6M | $1.8B | ||
| Q3 25 | $832.6M | $1.7B | ||
| Q2 25 | $837.2M | — | ||
| Q1 25 | $823.1M | — | ||
| Q4 24 | $893.3M | — | ||
| Q3 24 | $867.9M | — | ||
| Q2 24 | $882.0M | — | ||
| Q1 24 | $906.0M | — |
负债/权益比OFIXWOR
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $51.5M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $39.1M |
| 自由现金流率自由现金流/营收 | 7.6% | 11.9% |
| 资本支出强度资本支出/营收 | 4.9% | 3.8% |
| 现金转化率经营现金流/净利润 | — | 1.89× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXWOR
| Q4 25 | $27.7M | $51.5M | ||
| Q3 25 | $12.4M | $41.1M | ||
| Q2 25 | $11.6M | — | ||
| Q1 25 | $-18.4M | — | ||
| Q4 24 | $23.7M | — | ||
| Q3 24 | $11.7M | — | ||
| Q2 24 | $9.0M | — | ||
| Q1 24 | $-18.6M | — |
自由现金流OFIXWOR
| Q4 25 | $16.8M | $39.1M | ||
| Q3 25 | $2.5M | $27.9M | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | $-25.1M | — | ||
| Q4 24 | $15.2M | — | ||
| Q3 24 | $6.3M | — | ||
| Q2 24 | $-360.0K | — | ||
| Q1 24 | $-29.1M | — |
自由现金流率OFIXWOR
| Q4 25 | 7.6% | 11.9% | ||
| Q3 25 | 1.2% | 9.2% | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | -13.0% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | -0.2% | — | ||
| Q1 24 | -15.4% | — |
资本支出强度OFIXWOR
| Q4 25 | 4.9% | 3.8% | ||
| Q3 25 | 4.8% | 4.3% | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 5.6% | — |
现金转化率OFIXWOR
| Q4 25 | — | 1.89× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
WOR
| Building Products | $207.5M | 63% |
| Equity Method Investment Nonconsolidated Investee Other | $120.7M | 37% |
